Health Care Biotech and Pharmaceuticals

More

  • Disease expert on Zika: Americans shouldn't panic Friday, 29 Jan 2016 | 9:35 AM ET
    A banner is seen during an information campaign on the Zika virus by the Chilean Health Ministry at the departures area of Santiago's international airport, Chile, January 28, 2016.

    The Zika virus should not cause Americans to be "unduly alarmed just yet," says infectious disease expert Paul Roepe.

  • Gilead names Milligan as new CEO Friday, 29 Jan 2016 | 8:18 AM ET
    A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

    Gilead Sciences on Friday that John Milligan, currently president and chief operating officer, will be promoted to CEO and appointed to the board of directors.

  • Amgen beats estimates, raises full-year guidance Thursday, 28 Jan 2016 | 4:39 PM ET
    Amgen

    Amgen boosted guidance after it beat on fourth-quarter earnings, helped by sales of its rheumatoid arthritis drug Enbrel.

  • Drug companies can't bankrupt states: Mass. AG Thursday, 28 Jan 2016 | 3:20 PM ET
    Drug companies can't bankrupt states: Mass. AG

    Massachusetts Attorney General Maura Healey explains why it's worth investigating drug pricing and Gilead's practices.

  • Martin Shkreli slaps down rapper in vulgar video Thursday, 28 Jan 2016 | 3:31 PM ET
    Martin Shkreli and Rapper Ghostface Killah of the Wu-Tang Clan.

    The rap-fueled beef with Ghostface Killah was recorded while the pharma exec Martin Shkreli is free on $5 million bond.

  • Like big pharma, biotech is toxic: Trader Thursday, 28 Jan 2016 | 12:35 PM ET
    Like big pharma, biotech is toxic: Trader

    Health care is one of the biggest drags on the market right now because of the moves lower in biotech stocks. CNBC's Meg Tirrell looks ahead to biotech earnings out next week. The FMHR traders and Kate Moore, JPMorgan Private Bank chief investment strategist, discuss.

  • Theranos under fire Thursday, 28 Jan 2016 | 11:17 AM ET
    Theranos under fire

    Regulators warn that new Theranos lab in California is unsafe for patients, company says it's taking corrective action. CNBC's Meg Tirrell explains.

  • As Zika virus spreads, no vaccine in sight Thursday, 28 Jan 2016 | 11:34 AM ET
    Child neurologist Vanessa Van Der Linden observes the X-ray of a baby's skull with microcephaly at the hospital Barao de Lucena in Recife, Brazil, January 26, 2016.

    A safe vaccine for the Zika virus will likely not be available this year or the following year, an NIH official said Thursday.

  • Roche earnings miss forecasts Thursday, 28 Jan 2016 | 2:00 AM ET
    Roche earnings miss forecasts

    Severin Schwan, CEO of Roche, discusses his company's full year results, which came in below expectations.

  • Zika epidemic on US doorstep spurs vaccine hunt Thursday, 28 Jan 2016 | 7:40 AM ET

    The rapid spread of the zika virus has spurred the hunt for a cure, but the financial incentive and likely length of time for a vaccine are unclear.

  • Roche earnings fall short of forecasts Thursday, 28 Jan 2016 | 3:12 AM ET

    Drugmaker Roche on Thursday reported full-year earnings and a dividend slightly below forecasts and said it expected sales to grow low- to mid-single digit in 2016.

  • Your first trade for Thursday Wednesday, 27 Jan 2016 | 6:32 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Gilead may face legal action for pricing: Mass. AG Wednesday, 27 Jan 2016 | 2:45 PM ET
    The headquarters of Gilead Sciences in Foster City, Calif.

    Massachusetts AG Maura Healey said the costs of two drugs "may constitute an unfair trade practice in violation of Massachusetts law."

  • A step closer to a cure for type 1 diabetes Wednesday, 27 Jan 2016 | 8:00 AM ET
    A step closer to a cure for type 1 diabetes

    Scientists developed a device to prevent implanted insulin-producing cells from being attacked by the immune system for six months.

  • Novartis profits plunge Wednesday, 27 Jan 2016 | 7:54 AM ET
    Novartis profits plunge

    CNBC's Meg Tirrell breaks down the quarterly numbers on Biogen and Novartis.

  • Biogen profit beats Street estimates as Tecfidera shines Wednesday, 27 Jan 2016 | 7:55 AM ET
    A worker in a Biogen lab.

    Biogen's quarterly profit breezed past Wall Street's estimates, driven by higher demand for its key oral multiple sclerosis drug Tecfidera.

  • 2016 will be pivotal to health care: JP Morgan Wednesday, 27 Jan 2016 | 2:00 AM ET
    2016 will be pivotal to health care: JP Morgan

    Cathrin Petty, head of EMEA healthcare at JP Morgan, says 2016 will be a pivotal year for the health care industry due to new product launches and approvals, as well as commercial headwinds.

  • Novartis expects sales to be in line with 2015 Wednesday, 27 Jan 2016 | 2:00 AM ET
    Novartis expects sales to be in line with 2015

    CNBC correspondent Julia Chatterley reports on Novartis' 4th quarter net income of $2.7 billion, which was below forecasts.

  • The UK's biotech revolution Wednesday, 27 Jan 2016 | 2:30 AM ET
    The UK's biotech revolution

    Xavier Rolet, CEO of the London Stock Exchange, talks about the success pharma and health care companies have had raising capital in the U.K.

  • Donald Trump joins Democrats in voicing drug price concerns

    CNBC's Meg Tirrell highlights the increasingly popular political stance against increasing drug prices.

Contact Biotech and Pharma

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.